Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:600329's Gross Margin % is ranked better than 88.22% of 942
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs SHSE:600329: 75.19
Tianjin Pharmaceutical Da Ren Tang Group had a gross margin of 77.71% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Tianjin Pharmaceutical Da Ren Tang Group had a gross margin of 77.71% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Tianjin Pharmaceutical Da Ren Tang Group Gross Margin % Related Terms
Tianjin Pharmaceutical Da Ren Tang Group Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tianjin Pharmaceutical Da Ren Tang Group Gross Margin % Chart
Tianjin Pharmaceutical Da Ren Tang Group Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Tianjin Pharmaceutical Da Ren Tang Group's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tianjin Pharmaceutical Da Ren Tang Group Gross Margin % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) has a Gross Margin % of 77.71% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Tianjin Pharmaceutical Da Ren Tang Group and its competitors. This is 91% above median its historical median of 40.69. Over the past decade, Tianjin Pharmaceutical Da Ren Tang Group's Gross Margin % has ranged from 32.48 to 75.19. According to the industry distribution chart, Tianjin Pharmaceutical Da Ren Tang Group ranks #111 out of 942 companies in the Drug Manufacturers industry, placing it in the top 11.8%.
Is Tianjin Pharmaceutical Da Ren Tang Group's Gross Margin % too high?
Tianjin Pharmaceutical Da Ren Tang Group's current Gross Margin % of 77.71% is 91% above median its 10-year median of 40.69. Over the past 10 years, this metric has ranged from a low of 32.48 to a high of 75.19. The Drug Manufacturers industry median Gross Margin % is 48.54. Tianjin Pharmaceutical Da Ren Tang Group's value of 77.71% is 60.1% above this industry median. Based on the distribution chart, Tianjin Pharmaceutical Da Ren Tang Group ranks #111 out of 942 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Tianjin Pharmaceutical Da Ren Tang Group has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tianjin Pharmaceutical Da Ren Tang Group's Gross Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Tianjin Pharmaceutical Da Ren Tang Group ranks #111 out of 942 companies for Gross Margin %. This places Tianjin Pharmaceutical Da Ren Tang Group in the top 12% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.54. Tianjin Pharmaceutical Da Ren Tang Group's value of 77.71% is 60.1% above this benchmark. Historically, Tianjin Pharmaceutical Da Ren Tang Group's own Gross Margin % has ranged from 32.48 to 75.19 over the past decade. While the company's 10-year median is 40.69 vs. the industry median of 48.54, Tianjin Pharmaceutical Da Ren Tang Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 942 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tianjin Pharmaceutical Da Ren Tang Group's current Gross Margin % of 77.71% is 60.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Tianjin Pharmaceutical Da Ren Tang Group and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tianjin Pharmaceutical Da Ren Tang Group's current Gross Margin % is 77.71%, which is 91% above median its own 10-year median of 40.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tianjin Pharmaceutical Da Ren Tang Group stock overvalued right now?
Based on GuruFocus' analysis, Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥23.63, compared to a current price of ¥36.43 — trading 54.2% above its estimated fair value. The current Gross Margin % is 77.71%, which is 91% above median its 10-year median of 40.69 and 60.1% above the Drug Manufacturers industry median of 48.54. Tianjin Pharmaceutical Da Ren Tang Group's overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329), the current Gross Margin % is 77.71% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Overvalued in 2026?
Based on GuruFocus' analysis, Tianjin Pharmaceutical Da Ren Tang Group stock appears to be overvalued.
The current stock price of ¥36.43 is trading 54.2% above its estimated GF Value™ of ¥23.63.
GuruFocus considers Tianjin Pharmaceutical Da Ren Tang Group to be Significantly Overvalued.
Key valuation signals for SHSE:600329:
Gross Margin %: 77.71% (91% above median its 10-year median of 40.69)
GF Value™: ¥23.63 vs. price of ¥36.43 (54.2% above fair value)
Industry Position: 60.1% above the Drug Manufacturers median (#111 of 942)
No single metric tells the full story. See the SHSE:600329 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tianjin Pharmaceutical Da Ren Tang Group Business Description
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company is engaged in the production and sale of traditional Chinese medicine, Western medicine, healthcare products, and investment holding. It operates in two segments, namely the Chinese Medicine segment and the Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures Western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese medicine.
65GF Score
Get the complete analysis for SHSE:600329
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600329 has been successfully added to your 
